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Differential tumor infiltration by T-cells 
characterizes intrinsic molecular subtypes 
in breast cancer
M. Miyan1, J. Schmidt‑Mende2,3, R. Kiessling2, I. Poschke4† and J. de Boniface1,5*† 
Abstract 
Background: Molecular subtypes of breast cancer and presence of tumor‑infiltrating immune cells have both been 
implicated as important predictive and prognostic factors for improved risk stratification and treatment individualiza‑
tion of breast cancer patients. Their association, however, has not been studied in detail. The aim of this study was 
to evaluate the expression of the T cell markers CD8, FoxP3, CD3 and ζ‑chain in molecular subtypes of the invasive 
margin and tumor center of breast cancer and corresponding sentinel nodes and to deduct prognostic information 
from these findings.
Methods: Tumor and sentinel node sections from 177 patients with primary, invasive, unilateral early‑stage breast 
cancer were stained by immunohistochemistry and T‑cell phenotypes quantified manually. Clinical data were col‑
lected from medical records.
Results: The degree of T‑cell infiltration and expression of all markers differed significantly among the molecular 
subtypes, being highest in non‑luminal, more aggressive tumors: more T‑cell infiltration and higher expression of all 
markers were associated with hormone receptor negativity, higher proliferation and higher histological grades, but 
also with larger tumor size. Basal‑like tumors, and most remarkably their tumor centers, hosted the highest number of 
FoxP3+ T‑cells with an unfavorable ratio to cytotoxic CD8+ T‑cells. T‑cell infiltration was generally higher in the inva‑
sive margin than the tumor center. A scoring system based on densities of CD3 and CD8 could significantly separate 
molecular subtypes (p < 0.001).
Conclusions: Thus, immunological patterns with functional implications within each subtype are associated with 
prognostic factors. These findings should be further validated in studies using larger patient populations and longer 
follow‑up.
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Background
Breast cancer is the most common cancer among women, 
with an annual incidence of more than 1.6 million cases 
worldwide which is expected to increase further [1]. 
The past decades have seen significant improvements in 
patient survival, likely due to increased awareness, earlier 
detection through screening programs and advances in 
treatment [2]. Further improvements are dependent on 
precise classification for prognostication and prediction, 
and for the adequate choice of individualized treatment 
alternatives.
In order to modify and modernize breast cancer classi-
fication, Perou et al. [3] proposed five genetically distinct 
groups based on gene expression microarrays. These 
‘molecular subtypes’ have repeatedly been validated 
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[4]. There are commercially available multigene signature 
assays for subdivision of tumors into these molecular 
subtypes, however, estrogen and progesterone hormone 
receptors, the growth factor receptor Her2/Neu and the 
proliferation marker Ki-67 are acknowledged as clini-
cal surrogate markers [5]. These possess the advantage 
of being widely used in routine practice, affordable and 
available [6].
Apart from the above-mentioned molecular subtypes, 
immunological tumor-host interactions have received 
increasing attention as a prognostic and predictive tool 
[7, 8]. Immune evasion, i.e. the ability of the tumor to 
avoid or escape detection and elimination by the immune 
system, has been highlighted as one the emerging hall-
marks of cancer, necessary for tumor progression and 
metastasis [9]. Furthermore, tumors are able to modify 
anti-tumor immunological reactions, a development 
known as immunoediting [10]. Several T-cell phenotypes 
and functional markers have been investigated as poten-
tial prognostic and predictive factors in breast cancer, 
such as CD8+  T-cells [11, 12], FoxP3 [13, 14] and the 
ζ-chain of the T-cell receptor (see Additional file 1: Table 
S1) [15–17].
Based on tumor infiltration by T-cells, at least two 
prognostic scoring systems with promising clinical 
potential have been developed this far in other types of 
cancer. Firstly, Brandwein-Gensler includes the lympho-
cytic host response (LHR) in a risk model for head and 
neck squamous cell cancer [18]. This model correlates 
with disease progression and survival, even after adjust-
ment for clinical confounders, and a higher LHR has 
been associated with increased time to disease progres-
sion. Secondly, the ‘Immunoscore’ assesses the density of 
CD3+  and CD8+ T-cells in the tumor center (TC) and 
the invasive margin (IM). It was recently shown to out-
perform the TNM system’s prognostic power for early-
stage colorectal cancer [19, 20].
Conflicting evidence exists regarding the relative 
importance and significance of different T-cell pheno-
types, and it is likely that their importance and predictive 
capacity varies depending on breast cancer subtype and 
tumor microenvironment. Therefore, it is of considerable 
scientific interest to study T-cell infiltration in the con-
text of molecular subtypes.
Methods
A prospective study population of breast cancer patients 
(n  =  43) consecutively operated at the Department of 
Breast and Endocrine Surgery, Karolinska University 
Hospital, was enrolled in 2009–2010 for immunological 
analysis. In order to increase the study population, addi-
tional patients were identified from the prospective oper-
ation log database during the same time period, operated 
in a consecutive manner. Thus, the study population con-
sisted of 177 previously untreated patients with primary, 
unilateral invasive breast cancer without clinical signs of 
regional or distant metastasis. All patients were sched-
uled for sentinel lymph node biopsy and received adju-
vant treatment according to current treatment protocols.
Clinical parameters, as well as patient and tumor 
characteristics: i.e. age, tumor size, nodal status, TNM-
stage, estrogen and progesterone receptor status, Her2/
Neu-status, Ki-67 proliferative index, histological grade, 
histological subtype, LVI, adjuvant treatment, relapse 
and mortality was compiled from medical files. For 
subdivision into intrinsic molecular subtypes, the clini-
cal surrogate parameters of estrogen and progesterone 
receptor positivity, Her2/Neu-status, and Ki-67 labeling 
index were applied as described in the St Gallen consen-
sus report from 2013 [5]. Tumors were thus subdivided 
into the five categories luminal A, luminal B, luminal B/
Her2/Neu-overexpressing, non-luminal Her2/Neu-over-
expressing and basal-like (triple-negative).
Whole tissue sections of 177 tumors and their cor-
responding sentinel nodes were retrospectively col-
lected from the Department of Pathology at Karolinska 
University Hospital for immunological analysis. Before 
staining, 4  µm thick sections were cut from paraffin-
embedded tumor blocks, dewaxed in xylene and rehy-
drated in decreasing ethanol concentrations, from 100 to 
70 %. Pretreatment with citrate buffer (pH 6.0) was per-
formed. Subsequently, samples were heated 10–12  min 
in a microwave at 750 W up to 98 °C. To facilitate anti-
gen retrieval, samples were further boiled for 20  min 
at 350 W. Samples were then cooled in a water bath for 
20 min. Sections were incubated in 0.5 % H2O2 for 30 min 
to prevent endogenous peroxidase activity and thereafter 
washed in water followed by TBS (Triss-Buffer-Saline). 
After these initial steps, two different protocols ensued 
for CD3, ζ-chain- and CD8, FoxP3-staining, respectively.
CD3 and ζ‑chain‑staining
Unspecific binding sites were blocked using 1  % BSA 
(bovine serum albumin) in TBS for 30  min. Without 
prior washing, the primary antibody diluted in 1 % BSA 
was dripped on and the samples were incubated in a 
refrigerator overnight. For CD3, the primary antibody 
was rabbit-anti-human, Dako (A0452), 1:800. For the 
ζ-chain, the primary antibody used was mouse-anti-
human, Santa Cruz Biotechnology (sc1239), 1:4 000. The 
next day, samples were taken out from the refrigerator 
and washed in TBS 3 × 5 min. A biotinylated secondary 
antibody (Vector Laboratories, 1:200, goat-anti-rabbit, 
BA-1000 for CD3 and horse-anti-mouse, BA-2000 for 
CD3-ζ) in 0.2  % Triton-X in TBS was applied, and sec-
tions were incubated for 30 min. Meanwhile, the tertiary 
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antibody (ABC-Po, PK-6100, Vector Laboratories) was 
prepared using two units of Avidin, two units of Biotin 
and 96 units of 0.2 % Triton-X in TBS. The mix was left 
in room temperature for 30  min. After the secondary 
antibody had been applied for 30 min, washing in TBS 
for 3 × 5 min ensued. The tertiary antibody was applied 
30  min after being mixed and sections were once again 
incubated for 30  min, followed by another washing in 
TBS for 3 × 5 min. Then DAB-kit, SK-4100 (Vector Lab-
oratories) was used in accordance with the manufactur-
er’s description. Nuclear staining was done using Mayers 
HTX (Hematoxylin) and sections were washed in luke-
warm water. Sections were then dehydrated, and bathed 
for a few minutes in increasing concentrations of ethanol, 
from 70 to 100 %. Finally, they were bathed in xylene and 
mounted on a xylene-based assemblage-material.
FoxP3/CD8
Unspecific binding sites were blocked using 2.5  % 
horse-serum for 30  min. No washing was performed. 
Primary antibodies diluted in 1  % BSA [FoxP3: mouse-
anti-human, eBioscience (14-4777-82), 1:100 and CD 
8: rabbit-anti-human, Spring, SP Clone (M3162), 1:100] 
were mixed into the solution and incubated overnight 
in a refrigerator-tempered moisture chamber. The next 
day, sections were washed in TBS 3 × 5 min. Secondary 
antibodies [FoxP3: biotinylated horse-anti-mouse, Vec-
tor Laboratories (BA-2000) and CD8: ImPress peroxi-
dase, anti-rabbit, Vector Laboratories (MP-7401)] were 
added and then incubated for 30 min. During the incu-
bation time, the tertiary antibody (ABC-AP, AK 5000, 
Vector Laboraties) was prepared using one unit of Avi-
din, one unit of Biotin and 98 units of 0.2 % Triton X in 
TBS. After the secondary antibody had been applied for 
30 min, washing in TBS for 3 × 5 min ensued. The ter-
tiary antibody was applied 30 min after being mixed and 
sections were once again incubated for 30 min, followed 
by another washing in TBS for 3 ×  5  min. Vector Blue 
Substrate Kit, Vector Laboratories (SK-5300), was used 
in accordance with the manufacturer’s instructions, fol-
lowed by addition of DAB-kit, Vector Laboratories (SK-
4100). Nuclear staining was done using Mayers HTX 
(Hematoxylin) and sections were washed in lukewarm 
water. Finally, sections were mounted on water-based 
assemblage material.
Evaluation of occurrence and distribution of CD3, ζ‑chain, 
CD8 and FoxP3
Samples were analyzed by an experienced pathologist 
together with the student. Patient identification was 
coded to ensure a blinded assessment. Three areas of 
interest were selected: the tumor invasive margin, where 
the front of the tumor cells interact with the surrounding 
tumor stroma, the tumor center, and the paracortex of the 
sentinel node. Here, in the main T-cell area of the lymph 
node, T-cells encounter antigen-presenting cells deriv-
ing from the tumor and T-cell activation takes place. The 
pathologist assessed these three areas of interest in order 
to identify the high power field (HPF) per area showing 
the largest amount of T-cells expressing the respective 
marker for subsequent manual counting. For analysis of 
the number of cells expressing the marker of interest, 
both investigators analyzed samples independently of 
one another. Inter-individual accordance was assessed 
using approximately 20 samples and deemed to be suf-
ficient, although no statistical analysis was performed to 
assess a kappa-value. The software ImageJ (http://www.
imagej.nih.gov/ij/), which allows the user to mark already 
counted cells, was used to aid manual cell counting. Cells 
were counted in the selected HPF with the densest T-cell 
infiltration of the respective phenotype.
Assessment of lymphocytic host reaction
LHR was investigated in tissue sections using the defini-
tions provided by Brandwein-Gensler et al. [18].
Statistical analysis
All distributions were tested for normality using the Sha-
piro–Wilks test (if n < 50) or the Kolmogorov–Smirnov 
test (if n  >  50) and parametric or non-parametric tests 
were used accordingly. The Kruskal–Wallis test was used 
to assess differences in median expression between more 
than two groups in order to decrease the probability of 
type 1-errors. If the significance level was found to be 
below 0.05, the Mann–Whitney U test was used to test 
any difference between two separate groups specifically. 
When different areas were compared within the same 
individuals, Wilcoxon sum rank test for paired samples 
was used. Occasionally (when normality could not be 
rejected), Student’s t test and Levene’s test for equality 
of variance were used for the same purpose. Chi square 
cross-tabulation was used to test associations between 
two ordinal or nominal variables. Fisher’s exact test 
was used for equivalent purposes when the underlying 
assumptions of Chi Square cross-tabulation were not 
fulfilled. Bivariate correlations were tested using Pearson 
Correlation coefficient or Spearman’s Rank Correlation 
Coefficient depending on data normality. All statistical 
analyses were performed using IBM SPSS Statistics, ver-
sion 22.0 (SPSS Inc., Chicago, Illinois, USA). A two-tailed 
α < 0.05 was considered statistically significant.
Results
Overall, 177 patients were included. Patient and tumor 
characteristics are presented in Table  1. Median fol-
low-up time was 47  months (0–58). Seven patients 
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died, three of whose deaths were due to breast can-
cer. Recurrence was diagnosed in 12 patients, most 
commonly (seven patients) at a distant location. 
Local (within the same breast) and axillary recurrence 
occurred in three patients, respectively. One patient 
had both axillary and distant recurrences. Due to the 
low number of events, we do not report on survival 
analyses; these were performed but shown to not ren-
der significance even for established clinical prognos-
tic factors, confirming the unfeasibility of survival 
analysis in this cohort thus far.
Lymphocytic host response correlates positively 
with immunological markers and is associated with poor 
prognostic factors
Lymphocytic host response (LHR), categorized into 
four groups (negative, weak, moderate and strong) 
according to the original description [18], correlated 
positively with the density of all measured immuno-
logical markers (Spearman’s Rho 0.368–0.799, each 
p < 0.01). Tumors displaying higher degrees of LHR had 
significantly higher histological grades (p = 0.003) and 
proliferation (p < 0.001), and were negative for ER and 
PR (p < 0.001). LHR showed no relation to other clini-
cal parameters.
The five intrinsic molecular subtypes (luminal A, lumi-
nal B, luminal B Her2/Neu overexpressing, non-luminal 
Her2/Neu overexpressing and basal-like) differed con-
siderably in their respective LHR (p < 0.001). While the 
luminal (ER-positive) subtypes generally exhibited a 
negative or weak LHR, the non-luminal (ER-negative) 
ones displayed a strong or moderate LHR, as depicted in 
Fig.  1. In particular, large discrepancies were found for 
the luminal A subtype against the non-luminal subtypes 
(p < 0.001).
The density of T‑cell phenotypes differs between tumor 
areas
To better characterize the immune infiltrate, we per-
formed immunohistochemistry for total T-cells (CD3), 
cytotoxic T-cells (CD8), regulatory T-cells (FoxP3) and 
T-cell functionality (CD3-zeta-chain, see Additional 
file  1: Table  S1 for a description of the investigated 
markers). Representative images for CD8 and FoxP3 
are presented in Fig.  2. For all T-cell phenotypes, the 
mean number of infiltrating cells per high power field 
(HPF) was significantly higher in the invasive mar-
gin (CD3: 306.93  ±  203.32; CD8: 149.37  ±  108.68; 
FoxP3: 20.26  ±  26.72; CD3-zeta: 98.93  ±  103.09) 
than in the tumor center (CD3: 126.81  ±  119.35; 
CD8: 82.84  ±  83.86; FoxP3: 14.90  ±  25.47; CD3-zeta: 
31.11  ±  52.32; p  <  0.0001). The numbers of positive 
T-cells in the IM correlated positively with their TC 
equivalents for all markers (each p  <  0.001, Spear-
man’s Rho 0.415–0.752). Not surprisingly, densities of 
Table 1 Patient and tumor characteristics
Figures are N and (%) unless otherwise stated
a Median (range)
b The cut-off value being 20 %
N (%)
Age at operation (years)a 62 (32–91)

























Luminal A 88 (49.7)
Luminal B 46 (26.0)
Luminal B Her2/Neu‑overexpressing 17 (9.6)












Adjuvant endocrine therapy 151 (85.3)
Anti-Her2/Neu therapy (trastuzumab) 19 (10.7)
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all analyzed T-cell phenotypes (apart from CD-zeta the 
density of which was not analyzed in the SLN) were 
highest in the SLN (CD3: 1528.63  ±  485.81; CD8: 
344.14 ± 199.60; FoxP3: 71.66 ± 82.50). In 12 cases, an 
additional non-sentinel lymph node could be evaluated, 
but the densities of T-cell phenotypes did not differ from 
the SLN itself.
Density of T‑cell phenotypes differs significantly 
in different molecular subtypes
Overall, all studied T-cell phenotypes differed signifi-
cantly between molecular subtypes, both in the inva-
sive margin (CD3: p  =  0.013; CD8: p  <  0.001; FoxP3: 
p  <  0.001 and CD3-ζ: p  <  0.007) and the tumor center 
(CD3: p = 0.001; CD8: p = 0.042; FoxP3: p < 0.001 and 
CD3-ζ: p =  0.002). The density of all T-cell phenotypes 
in both invasive margin and tumor center was consist-
ently lowest in the luminal A subtype. Interestingly, the 
more aggressive subtypes each had a distinct profile, with 
basal-like tumors showing the highest FoxP3 and CD8 
densities, Her2/neu overexpressing tumors the highest 
CD3-ζ density and luminal B Her2/neu positive tumors 
the highest CD3 density in the invasive margin and 
CD8 levels similar to basal-like tumors. All 19 basal-like 
tumors had some degree of FoxP3 positivity while 29 of 
81 (36  %) luminal A-tumors were entirely negative for 
Fig. 1 Lymphocytic host response within each molecular subtype: numbers represents percentage of color-coded grades (negative, weak, moder‑
ate, strong) within each tumor subtype
Tumor periphery high CD8 high FoxP3 Tumor center high CD8 low FoxP3 Tumor center low CD8 no FoxP3
a b c
Fig. 2 Immunohistochemical staining of whole tumor sections. a Tumor periphery displaying high densities of CD8+ (brown) and FoxP3+ (dark 
blue) T‑cells. b Tumor center with high density of CD8+ but few FoxP3+ T‑cells. c Tumor center with few CD8+ and no FoxP3+ T‑cells
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FoxP3. Figure  3 shows numbers of positive T-cells for 
each marker per subtype and tumor area, highlighting 
significant differences between subtypes with the luminal 
A category as reference group.
A common clinical classification is to separate lumi-
nal (ER-positive) tumors from non-luminal ones 
(ER-negative). Comparing these two groups, all densities 
of T-cell phenotypes were significantly higher in the non-
luminal subtypes (p < 0.001) apart from CD8 density in 
the tumor center.
The number of T-cell phenotypes in the SLN and 
non-SLNs was not significantly different when compar-
ing molecular subtypes or luminal versus non-luminal 
tumors.
T‑cell functionality differs among subtypes
In order to assess the functionality of the T-cells within 
different subtypes, the number of ζ-chain+  T-cells in 
relation to CD3+ T-cells was calculated as a ratio. Inter-
estingly, this ratio did not differ significantly between the 
different subtypes, however, when comparing luminal 
versus non-luminal tumors, the latter has a significantly 
lower ratio in the tumor center (p = 0.012) but a higher 
ratio in the invasive margin (p  =  0.022). The ζ-chain/
CD3-ratio positively correlated with LHR (Spearman’s 
Rho 0.581, p < 0.01).
The suppressive versus cytotoxic equilibrium was 
analyzed using a ratio of FoxP3+  to CD8+  , which dif-
fered significantly when comparing all subtypes in both 
invasive margin and tumor center (p = 0.003). This ratio 
was consistently lower in the invasive margin than in the 
tumor center. The highest ratio was found in basal-like 
tumors (tumor center 0.62  ±  0.64 and invasive margin 
0.19 ± 0.15) and the lowest in luminal A tumors (tumor 
center 0.15  ±  0.29 and invasive margin 0.09  ±  0.12). 
Here, too, the luminal tumors generally had lower ratios 
than their non-luminal counterparts, especially in the 
tumor center (p < 0.001). Finally, the cytotoxic potential 
of the T-cells was assessed by creating a ratio of CD8+ to 
CD3+  T-cells. This ratio did not differ significantly 
between subtypes. No differences between subtypes were 
found in SLNs.
T‑cell phenotypes in the tumor and molecular subtypes are 
related to established clinical parameters
Higher densities of T-cell phenotypes were invariably 
associated with negative prognostic factors as meas-
ured by routine histopathological assessment. This 
held true for all markers with significances listed in 
Table  2. Interestingly, a higher density of CD8+  and 
CD3+  T-cells in the paracortex of the SLN was asso-
ciated with the debated prognostic factor of lympho-
vascular tumor invasion (LVI). A higher ζ-chain/CD3 
ratio was associated with ER (p  =  0.022 and 0.012 
for invasive margin and tumor center), PR negativity 
(p = 0.003 for tumor center), and ductal tumor histol-
ogy. While the CD8/CD3 ratio was higher in the SLN 
of younger individuals, it was also higher in the tumor 
center of patients 50  years of age or older. A higher 
Fig. 3 Numbers of T‑cells per high power field (HPF) within each 
tumor molecular subtype and tumor area. a CD3, b CD8, c FoxP3 and 
d CD3‑ζ. Significant subgroup differences with the luminal A subtype 
as reference category are highlighted with *p < 0.05; **p < 0.01 and 
***p < 0.001
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FoxP3/CD8 ratio was significantly associated with 
ER negativity (p =  0.031 and  <0.001 for invasive mar-
gin and tumor center), high proliferation (both areas 
p < 0.001) and tumor histological grade (p = 0.013 and 
0.034, respectively).
Molecular subtypes were confirmed to be related to 
established clinical parameters: while 40  % of all basal-
like tumors affected patients below the age of 50, all 
tumors of the luminal B Her2/Neu-positive subtype 
were found in patients above 50 years of age. Luminal A 
tumors also predominantly affected the older age group, 
in 83.9 % of cases. Non-luminal tumors were associated 
with higher histological grades. Lymphovascular inva-
sion (LVI) was most commonly observed in the luminal 
B Her2/Neu-positive subtype (35.7  %), and most infre-
quently in luminal A tumors (7.7 %). No significant asso-
ciation, however, was found regarding tumor size, nodal 
status, TNM stage or disease relapse.
Table 2 Density of T-cell phenotypes in relation to established prognostic markers
Significant values always represent a higher T-cell infiltration for any negative prognostic group
CD8 FoxP3 ζ‑chain CD3
Invasive margin
Age at operation (<50 vs ≥50 years) n.s. n.s. n.s. n.s.
Tumor size (T1 vs T2 vs T3) n.s. n.s. n.s. n.s.
Nodal status (N0 vs N1) n.s. n.s. n.s. n.s.
Tumor stage (TNM) n.s. n.s. n.s. p = 0.027
Estrogen receptor status (pos. vs neg.) n.s. p = 0.001 p = 0.001 p = 0.025
Progesterone receptor status (pos. vs neg.) p = 0.004 p = 0.044 p = 0.001 p = 0.002
Her2/Neu status (FISH) (amplified/not amplified) p = 0.038 n.s. p = 0.039 n.s.
Proliferation (Ki‑67) (high vs low) p = 0.001 p < 0.001 p = 0.024 p = 0.027
Nottingham histological grade p < 0.001 p < 0.001 p = 0.051 p = 0.030
Histological subtype (ductal vs lobular) n.s. n.s. p = 0.030 n.s.
Lymphovascular invasion (pos. vs neg.) n.s. n.s. n.s. n.s.
Tumor center
Age at operation (<50 vs ≥50 years) n.s. n.s. n.s. p < 0.001
Tumor size (T1 vs T2 vs T3) p = 0.009 n.s. n.s. p = 0.001
Nodal status (N0 vs N1) n.s. n.s. n.s. n.s.
Tumor stage (TNM) p = 0.010 p = 0.050 n.s. p = 0.001
Estrogen receptor status (pos. vs neg.) p = 0.001 p < 0.001 p < 0.001 p < 0.001
Progesterone receptor status (pos. vs neg.) p = 0.001 p = 0.009 p < 0.001 p = 0.001
Her2/Neu status (FISH) (amplified/not amplified) n.s. n.s. n.s. p = 0.040
Proliferation (Ki‑67) (high vs low) p = 0.045 p < 0.001 p < 0.001 p < 0.001
Nottingham histological grade p = 0.002 p = 0.005 p = 0.009 p = 0.001
Histological subtype (ductal vs lobular) n.s. n.s. n.s. n.s.
Lymphovascular invasion (pos. vs neg.) n.s. n.s. n.s. n.s.
Sentinel node paracortex
Age at operation (<50 vs ≥50 years) p < 0.001 n.s. n.s. n.s.
Tumor size (T1 vs T2 vs T3) n.s. n.s. n.s. n.s.
Nodal status (N0 vs N1) n.s. n.s. n.s. n.s.
Tumor stage (TNM) n.s. n.s. n.s. n.s.
Estrogen receptor status (pos. vs neg.) n.s. n.s. n.s. n.s.
Progesterone receptor status (pos. vs neg.) n.s. n.s. n.s. n.s.
Her2/Neu status (FISH) (amplified/not amplified) p = 0.022 n.s. n.s. n.s.
Proliferation (Ki‑67) (high vs low) p = 0.021 n.s. n.s. n.s.
Nottingham histological grade n.s. n.s. n.s. n.s.
Histological subtype (ductal vs lobular) n.s. n.s. n.s. n.s.
Lymphovascular invasion (pos. vs neg.) p = 0.032 n.s. n.s. p = 0.006
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An immunological score based on CD3 and CD8 separates 
molecular subtypes
In order to develop a scoring system based on immuno-
logical markers that could accurately separate the molecu-
lar subtypes from one another, the density of CD8+  and 
CD3+ T-cells in both tumor areas was compounded and 
categorized as either high or low. Samples were excluded if 
the value of either CD8 or CD3 was missing. Samples were 
divided into three groups: score I, with tumors exhibiting 
low density of both markers; score II, tumors displaying 
high density of either marker (in CD3high but CD8low cases 
most likely CD4-dominated tumors) and score III, tumors 
with high density of both T-cell phenotypes. CD3 and CD8 
were selected in accordance with the immunological score 
for colorectal cancer described earlier [20].
In total, 125 samples could be assessed. Tumors dis-
played substantially different immunological scores 
among the molecular subtypes (p < 0.001), with basal-like 
tumors predominantly showing a high, and luminal A 
tumors a low score. Figure 4 illustrates the percentage of 
tumors within each immunological score for each molec-
ular subtype.
Discussion
This report describes differential densities of T-cells 
expressing the markers CD8, FoxP3, ζ-chain and CD3 
in different molecular subtypes of breast cancer and 
their sentinel lymph nodes. We have here shown that 
molecular subtypes exhibit different densities of all ana-
lyzed T-cell phenotypes and that higher densities are 
associated with more aggressive tumor subtypes. We 
could further show that an immunological score based 
on CD3+ and CD8+ T-cells markedly differed between 
tumor subtypes.
The presence of tumor-infiltrating lymphocytes has 
repeatedly been shown to correlate with breast cancer 
prognosis and treatment response [11–16]. One of the 
here applied parameters, the lymphocytic host response 
(LHR) as described by Brandwein-Gensler [18], takes all 
lymphocytes into account and is based on routine hema-
toxylin-eosin staining, while all other parameters are spe-
cific T-cell markers detected by immunohistochemistry. 
Interestingly, the overall lymphocytic response yielded 
very similar results to the more sophisticated immuno-
histochemical analysis, despite the notion of functional 
heterogeneity in tumor-infiltrating lymphocytes: no 
marker had any superior or inferior capacity to illustrate 
differences among subtypes. Even though we could show 
that expression of FoxP3 seems to be a specific feature 
of basal-like tumors, our results suggest that the over-
all T-cell infiltration, rather than infiltration of specific 
phenotypes, separates the molecular subtypes. Luminal 
(ER+) subtypes were denoted by a low immunologi-
cal response while non-luminal (ER−) subtypes showed 
clear signs of an immunological host response. The lumi-
nal A subtype in particular distinguished itself with a 
low immunological response: only 2.4  % of all luminal 
A tumors had a strong LHR, in contrast to 41.7 % of the 
non-luminal subtypes. These findings are in support of 
several reports of non-luminal tumors generally exhibit-
ing a higher degree of tumor-infiltration by lymphocytes 
[21, 22], even though there are contrary results, too [23]. 
The interesting question is why differential immune infil-
tration should occur in breast cancer, and how it is asso-
ciated with prognosis. It seems feasible to assume that 
the infiltration of immune cells should reflect underly-
ing biological properties of the tumor [20]. Differential 
gene expression, on which the distinction of molecular 
Fig. 4 Distributions of immunological scores within each subtype. Numbers represent the percentage of each score (I–III) within each molecular 
subtype
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subtypes is based, may cause differences in vasculariza-
tion, lymphatic vessel density, antigenicity, chemokine 
milieu or cytokines. The occurrence of high endothelial 
venules, for example, is associated with lymphocytic infil-
tration and corresponds to a more favorable prognosis 
in breast cancer, however, an association with molecular 
subtypes has not yet been explored [24]. Cytotoxic T-cell 
responses are increasingly found to be directed against 
mutated epitopes predicted to be immunogenic, and are 
associated with better patient survival [25]. These inher-
ent distinctions may explain why the subtypes, originally 
defined by dissimilar gene expression, exhibit inher-
ently differential densities of T-cells. We have previously 
shown that signs of immunological dysfunction can be 
detected in the tumor, and even in peripheral blood, of 
patients with early-stage disease and limited tumor bur-
den [17, 26]. While it became aggravated with tumor 
progression, these studies suggest that the immune envi-
ronment is shaped relatively early during breast cancer 
development.
Interestingly, subtypes associated with a poor prognosis 
generally had higher numbers of each T-cell phenotype, 
including those phenotypes that should imply a favora-
ble prognosis, such as CD8+  cytotoxic T cells. While it 
seems somewhat counter-intuitive at first glance, the 
higher degree of lymphocytic response, however, predicts 
an improved response to both adjuvant and neoadjuvant 
treatment [7, 14, 27]. Consequently, each tumor subtype 
probably has an inherent degree of infiltration of T-cells, 
and any prognostic deductions should therefore be done 
with these inherent differences in mind. Especially in 
basal-like and Her2/Neu-overexpressing breast cancer, it 
has been suggested that a subdivision in tumors with high 
and low levels of tumor-infiltrating lymphocytes should 
be attempted for potentially adoptive treatment [28].
In addition, our results suggest that some subtypes 
might be more likely to respond to immunotherapeu-
tic approaches than others. For example, a first clini-
cal trial targeting the checkpoint inhibitory molecule 
PD1 showed promising results in patients with meta-
static triple-negative tumors [29]. In our study the 
related basal-like subtype had the strongest degree of 
immune infiltration, in agreement with studies showing 
that basal-like tumors are the subtype most frequently 
exhibiting PD-L1-positive tumor cells as well as immune 
infiltrate, which correlated with T-cell infiltration and a 
better prognosis [30]. Of note, some studies found PD-L1 
to correlate with poor survival [31]. This likely reflects 
omission of subtype-specific analysis and/or failure to 
detect PD-L1 expression, which is IFNγ dependent, in 
poorly infiltrated subtypes. Such discrepancies illustrate 
the importance of taking into account the differential 
immune infiltration patterns within the cancer subtypes.
Another important finding is the fact that all tumor 
subtypes generally exhibited a more pronounced infiltra-
tion in the invasive margin than in the tumor center. This 
is in agreement with findings from other tumor entities 
that show that it can be difficult for T-cells to infiltrate 
into tumors, especially those with a large stromal compo-
nent, due to physical barriers or the hostile tumor micro-
environment [32]. Interestingly, high T-cell densities in 
both the invasive margin and the tumor center predict 
better survival in colorectal cancer patients, where a 
‘tumor-observing’ immune response around the invasive 
margin is commonly found [33]. Importantly, we also 
observed a difference in the proportion of immune cells 
present at different sites: all tumor types showed a higher 
ratio of FoxP3+ cells to CD8+ cells in the tumor center, 
which is coherent with reports showing that tumors can 
recruit regulatory T-cells as part of their immune escape 
mechanism, and that these are better adapted to the 
tumor microenvironment, as they for example are more 
resistant to reactive oxygen [34, 35]. This would also be 
in line with the decreased detection of the CD3-zeta 
chain in the tumor center, as this molecule is known to be 
down-regulated under conditions of oxidative stress.
To the best of our knowledge, no study has yet evalu-
ated the relationship between T-cell densities in breast 
cancer sentinel lymph nodes and molecular subtypes. 
Compared to our observations in tumor tissue, sentinel 
lymph node analysis yielded far fewer inter-subtype dif-
ferences. Our study population, however, consisted of 
clinically node-negative patients, and in 70 % of patients, 
node negativity was confirmed by histopathology. Some 
other studies have seen associations between increased 
FoxP3 expression in sentinel nodes and nodal metasta-
sis [36], while others did not [37]. Considering that dif-
ferent subtypes have different propensities of developing 
nodal metastasis [38], differential FoxP3 expression could 
possibly have been detected had the study included 
later-stage patients. The only marker which differed sig-
nificantly among molecular subtypes in the sentinel node 
was CD8, with higher densities being seen in the luminal 
B Her2 positive-subtype compared to luminal A tumors. 
This may reflect the general immunogenicity of this 
tumor subtype, as luminal B Her2 tumors also had the 
highest number of tumor-infiltrating CD8+ T-cells. Sim-
ilarly, this subtype had the highest degree of LVI, which 
may explain the association with CD8+ accumulation in 
the sentinel node.
The immunoscore developed for colorectal cancer pre-
dicts relapses among early-stage tumors more accurately 
than classical TNM staging and consequentially bears 
therapeutic implications; patients at high risk could poten-
tially benefit from adjuvant treatment not normally given in 
early-stage disease [19, 20]. De Kruijf et al. [39] used a panel 
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of immunological markers to construct seven immune sub-
types in early breast cancer based on biological rationale. 
After an initial training set, these immune subtypes differed 
significantly in a multivariate analysis for relapse-free time 
in an independent validation set. These results indicate that 
using immunological markers for risk stratification purposes 
has potential also in the setting of breast cancer. Analogously, 
we have here shown that a scoring system based on densi-
ties of CD3+  and CD8+  T-cells significantly distinguishes 
molecular subtypes. Since the subtypes predict prognosis, 
and densities of immunological markers are known to do 
likewise, further research should compare long-term survival 
and relapse data among these different immunological scores, 
potentially separating high-risk patients within each subtype.
Conclusions
Molecular subtypes of breast cancer exhibit differential 
tumoral densities of CD8+  , FoxP3+  , ζ–chain+  and 
CD3+  T-cells. Large variations were observed within 
each tumor subtype, especially in quantity, rather than 
functionality of T-cells. This may have prognostic impli-
cations but needs to be validated using a larger patient 
population with longer follow-up time.
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